Literature DB >> 15703955

Severe, refractory type II essential mixed cryoglobulinemia treated with 2-chlorodeoxyadenosine and mycophenolate mofetil.

Douglas E Gladstone1, Marc G Golightly, Kenneth W Zamkoff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15703955     DOI： 10.1007/s00296-004-0577-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  7 in total

1.  2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.

Authors:  Donna M Weber; Meletios A Dimopoulos; Kay Delasalle; Kim Rankin; Maria Gavino; Raymond Alexanian
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

2.  Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents.

Authors:  E M Eugui; A Mirkovich; A C Allison
Journal:  Transplant Proc       Date:  1991-04       Impact factor: 1.066

Review 3.  Cryoglobulins.

Authors:  C Ferri; A L Zignego; S A Pileri
Journal:  J Clin Pathol       Date:  2002-01       Impact factor: 3.411

4.  Cryoglobulinemia--a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity.

Authors:  M Meltzer; E C Franklin; K Elias; R T McCluskey; N Cooper
Journal:  Am J Med       Date:  1966-06       Impact factor: 4.965

5.  Biologic and clinical significance of cryoglobulins. A report of 86 cases.

Authors:  J C Brouet; J P Clauvel; F Danon; M Klein; M Seligmann
Journal:  Am J Med       Date:  1974-11       Impact factor: 4.965

6.  Mycophenolate mofetil decreases antibody production after cardiac transplantation.

Authors:  Marlene L Rose; John Smith; Georges Dureau; Anne Keogh; Jon Kobashigowa
Journal:  J Heart Lung Transplant       Date:  2002-02       Impact factor: 10.247

7.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

Authors:  R A Luqmani; P A Bacon; R J Moots; B A Janssen; A Pall; P Emery; C Savage; D Adu
Journal:  QJM       Date:  1994-11
  7 in total
  2 in total

1.  Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab.

Authors:  David Chu; Michelle Stevens; Douglas Edward Gladstone
Journal:  Rheumatol Int       Date:  2007-04-19       Impact factor: 2.631

Review 2.  Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?

Authors:  Chalermrat Bunchorntavakul; Robert Mitrani; K Rajender Reddy
Journal:  J Clin Exp Hepatol       Date:  2017-12-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.